**Case Study**

**Successful Secondary Umbilical Cord Blood Transplantation for Graft Failure in Acute Myelogenous Leukemia, Treated with Modified One-Day Conditioning Regimen, and Graft-Versus-Host Disease Prophylaxis Consisting of Mycophenolate and Tacrolimus**

Noriaki Kawano,1) Takuro Kuriyama,1) Shuro Yoshida,2) Ikuo Shimizu,3) Hakaru Kobayashi,3) Katsuto Takenaka,4) Naoyuki Uchida,5) Akiyoshi Takami,6) Kiyoshi Yamashita,1) Akira Ueda,1) and Ikuo Kikuchi1)

Although graft failure (GF) is a fatal and life-threatening complication of umbilical cord blood transplantation (CBT), the standard treatment has not been established. We describe the case of a 28-year-old man diagnosed with acute myelogenous leukemia with myelodysplasia-related changes harboring a normal karyotype. This patient underwent 2 courses of idarubicin and cytosine arabinoside therapy, and 3 courses of high-dose cytosine arabinoside therapy. Subsequently, he underwent high-dose chemotherapy (total body irradiation and cyclophosphamide) followed by first CBT. Primary GF occurred after post-immunological reaction and hemophagocytic lymphohistiocytosis, and was diagnosed on day 27 after the first CBT. Therefore, the patient underwent secondary CBT for GF treated with a modified one-day conditioning regimen consisting of fludarabine (30 mg/m², 3 days), cyclophosphamide (2 g/m²), and total body irradiation (2 Gy), and graft-versus-host disease prophylaxis consisting of mycophenolate and tacrolimus. Consequently, the patient achieved neutrophil engraftment on day 17 after the second CBT. During the clinical course of the second CBT, the main complications were sepsis, BK virus-associated cystitis, and acute graft-versus-host disease (skin, grade 2, stage 3). After these treatments, the patient was disease-free for 39 months. Our case suggests that these treatments may be feasible, safe, and effective for the treatment of patients with GF. This case study may be helpful to physicians who directly care for GF patients, and may provide a future direction for a more efficient treatment modality. [[J Clin Exp Hematop 55(2) : 89-96, 2015]]

**Keywords:** graft failure in umbilical cord blood transplantation, post-immunological reaction, hemophagocytic lymphohistiocytosis, modified one-day conditioning regimen, mycophenolate

**INTRODUCTION**

Acute myelogenous leukemia (AML) is an acute-onset hematological malignancy that is characterized by the clonal proliferation of myeloid blasts (> 20%).1,3 With the development of diagnostic methods such as identifying chromosomal abnormalities, and the development of novel treatments, including bone marrow transplantation, dramatic improvements were achieved in the prognosis of hematological malignancy patients.2-5 Umbilical cord blood transplantation (CBT) has been increasingly performed in recent years in patients without an HLA-identical sibling or non-sibling donor.6,7 However, graft failure (GF) is a fatal and life-threatening complication of umbilical CBT that is characterized by a lack of donor cells (primary GF) or a loss of donor cells after
initial engraftment (secondary GF). Although the prognosis of GF remains poor, a standard treatment has not been established owing to the absence of randomized trials. Here, we report the case of a patient with successful secondary umbilical CBT for GF in AML, treated with a short-term reduced-intensity conditioning regimen consisting of fludarabine, cyclophosphamide, and total body irradiation, and graft-versus-host disease (GVHD) prophylaxis consisting of mycophenolate (MMF) and tacrolimus (FK).

CASE REPORT

A 28-year-old man with anemia and thrombocytopenia was referred to a regional hospital in October 2011. On admission, he was normotensive (108/60 mmHg) and had a heart rate of 66 beats/minute. On physical examination, he was found to have petechiae. Laboratory findings showed a hemoglobin concentration of 8.7 g/dL, platelet count of 77 × 10^9/L, and white blood cell count of 3.94 × 10^3/µL, with 1.0% metamyelocytes, 0.5% eosinophils, and 41.5% blasts. Serum lactate dehydrogenase level was elevated to 339 IU/L (Table 1). Prior pancytopenia was not observed by annual health check-up.

Bone marrow aspirate was hypercellular and had abnormal blast cells (27.0%) (Fig. 1A-1E). Blast cells were positive for myeloperoxidase (MPO) stain (Fig. 1F). Dysplastic features were present in all 3 hematopoietic lineages (Fig. 1A-1E).

Flow cytometric analysis performed on admission revealed the presence of surface markers for CD13, CD33, CD34, and HLA-DR. Chromosomal analysis showed a normal karyotype: 46, XY. Other screening molecular analyses of the leukemia were performed, such as PML-RARA, AML1-ETO, CBFB-MYH11, NUP98-HoxA9, ETV6-AML1, E2A-HEL, SIL-TAL-1, MLL-AF4, MLL-AF6, MLL-AF9, and MLL-ELM. All of these molecular analyses of the leukemia resulted in negative findings. On the basis of these cytogenetic and flow cytometric findings, we finally diagnosed the patient with AML with myelodysplasia-related changes.

Therefore, we immediately started idarubicin and cytosine arabinoside (IDA/Ara C) therapy on admission. After these treatments, the patient showed induction failure, which was suggested by the presence of residual myeloid blasts (13.0%) in the bone marrow. Subsequently, we repeatedly administered IDA/Ara C therapy as a re-remission induction therapy. After repeated IDA/Ara C therapy, the patient showed a complete response in December 2012. Post-remission therapy consisted of 3 courses of high-dose cytosine arabinoside therapy. After this treatment, the patient retained a complete response. Subsequently, the patient underwent high-dose chemotherapy and allogeneic bone marrow transplantation because a poor outcome was reported under 2 courses of induction therapy for complete remission, as well as the presence of the morphologic myelodysplastic features at diagno-

Table 1. Laboratory findings at admission

| (Peripheral cell count) | (Serum Chemistry) | (Coagulation) |
|-------------------------|-------------------|---------------|
| WBC                     | 3.94 × 10^3/µL    | T. Bil 0.8 mg/dL |
| PROMYE                  | 0.0%              | AST 64 IU/L |
| MYE                     | 0.0%              | ALT 104 IU/L |
| META                    | 1.0%              | ALP 274 IU/L |
| STAB                    | 0.0%              | LDH 339 IU/L |
| SEG                     | 13.0%             | CK 58 IU/L |
| LYMPH                   | 43.0%             | Na 142 mEq/dL |
| MONO                    | 1.0%              | K 3.7 mEq/dL |
| EOSIN                   | 0.5%              | Cl 108 mEq/dL |
| BASO                    | 0.0%              | Ca 9.2 mg/dL |
| BLAST                   | 41.5%             | BUN 10.2 mg/dL |
| RBC                     | 268 × 10^3/µL     | Cr 0.6 mg/dL |
| Hb                      | 8.7 g/dL          | UA 5.3 mg/dL |
| Hct                     | 23.9 %            | Ferr 870 ng/mL |
| MCV                     | 89.2 fl           | TP 7.1 g/dL |
| MCHC                    | 36.4 %            | ALB 4.9 g/dL |
| CR                   | 7.7 × 10^4/µL     | CRP 0.02 mg/dL |
| Ret                     | 1.0%              | |

WBC, white blood cell count; RBC, red blood cell count; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin concentration; Ph, platelet count; T. Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; CK, creatine kinase; BUN, blood urea nitrogen; Cr, creatinine; UA, uric acid; Ferr, ferritin; TP, total protein; ALB, albumin; CRP, C-reactive protein; PT, prothrombin time; PT (INR), prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fibr, fibrinogen; FDP, fibrin/fibrinogen degradation products.
sis. As the patient had no HLA-identical sibling or non-sibling donor, we selected umbilical CBT (Table 2). Anti-HLA antibody was not present in this case. The patient underwent high-dose chemotherapy with a conditioning regimen in the first complete remission, including total body irradiation (12 Gy) and cyclophosphamide (120 mg/kg) on days 2 to 6, and the first allogeenic bone marrow transplantation from an HLA-2-locus-mismatched cord blood donor, containing $2.7 \times 10^7$ cells/kg and $1.6 \times 10^5$ CD34+ cells/kg, in June 2012. Acute GVHD (aGVHD) prophylaxis included short-term methotrexate (15 mg/m² on day 1 and 10 mg/m² on days 3 and 6) and cyclosporine treatment. Fever and skin rash were observed on day 13. Subsequently, elevation of lactate dehydrogenase (903 IU/L) and ferritin (11,000 ng/mL) occurred on day 17. Bone marrow examination showed a dominance of lymphocytes and 7% hemophagocytosis with hypocellular bone marrow (NCC 1,500/µL) at the first transplantation on day 18 (1G-1I).

Fig. 1. Bone marrow findings at diagnosis (1A-1F) and at first transplantation on day 18 (1G-1I). A bone marrow smear showing the proliferation of blasts with dysplastic features in all 3 hematopoietic lineages. Bone marrow aspirate demonstrating a hypercellular bone marrow and abnormal blast cells (27.0%) (black arrow heads) (1A-1D). Blast cells were positive for myeloperoxidase (MPO) stain (1F). Dysplastic features were present in all 3 hematopoietic lineages (1A-1C). In the myeloid series, dysgranulopoiesis in abnormal cytoplasmic granules and pleomorphic nuclear forms were detected (green arrow heads) (1B). In the erythroid series, dyserythropoiesis was observed in pleomorphic nuclear forms, ringed sideroblasts, and nuclear-cytoplasmic dysynchrony (red arrow heads) (1C-1E). In the megakaryocyte series, bizarre nuclear figures, decreased ploidy, separated nuclei (so-called nuclear dispersion), and small micro-megakaryocytes were present (blue arrow heads) (1E). Cells were positive for MPO stain; > 3% of the blast cells stained positive for MPO (yellow arrow heads) (1F). Bone marrow examination showed a dominance of lymphocytes and 7% hemophagocytosis with hypocellular bone marrow (NCC 1,500/µL) at the first transplantation on day 18 (1G-1I).
HHV-6), Epstein-Barr virus, cytomegalovirus (CMV), herpes simplex virus, or varicella-zoster virus DNA. Together, these findings supported a diagnosis of pre-engraftment immunological reaction (PIR) and hemophagocytic lymphohistiocytosis (HLH).

Next, we administered prednisolone to treat the PIR and HLH. This treatment led to resolution of the fever and skin rash. However, the neutrophil count did not exceed 500/µL during the first CBT clinical course. Subsequent bone marrow examination still showed a dominance of lymphocytes and 2% hemophagocytosis, with hypocellular bone marrow (NCC 1,100/µL) on day 27. Moreover, bone marrow chimerism analysis showed recipient chimerism of > 95%. Consequently, we made a diagnosis of primary GF on day 27. At this time, the patient showed a good performance status (PS: 0), an absence of liver and renal dysfunction, and no infection. Thus, in our case, risk assessment using the Hematopoietic Cell Transplantation-Specific Comorbidity Index was zero. Therefore, the patient underwent a second CBT from an HLA-2-locus-mismatched cord blood donor, containing 2.6 × 10^7 cells/kg and 1.2 × 10^5 CD34+ cells/kg (Table 2). To prevent GF, the patient underwent a short-term reduced-intensity conditioning regimen, consisting of fludarabine (30 mg/m², 3 days), cyclophosphamide (2 g/m²), and total body irradiation (2 Gy), and GVHD prophylaxis consisting of MMF and FK on day 38 after the first CBT. Neutrophil engraftment (> 0.5 × 10^9/L) and platelet engraftment (> 50 × 10^9/L without transfusion) were achieved on days 17 and 28, respectively.

During the clinical course of the second CBT, the main

### Table 2. HLA profile of sibling donor and cord blood using 1st CBT and 2nd CBT

|            | HLA-A | HLA-B | HLA-C | HLA-DR | TNC          | CD34+ cells |
|------------|-------|-------|-------|--------|--------------|-------------|
| Patient    | 0201  | 2601  | 5101  | 6701   | 0304 0701 1201 1454 |             |
| CB1        | 0201  | 0207  | 5101  | 5603   | 0102 0304 1201 1454 | 2.7 × 10^7/kg | 1.6 × 10^7/kg |
| CB2        | 0201  | 2602  | 4801  | 5401   | 0102 0803 1201 1405 | 2.6 × 10^7/kg | 1.2 × 10^7/kg |
| Sister     | 0201  | 3101  | 0702  | 6701   | 0701 0701 1201 1454 |             |

HLA, human leukocyte antigen; CBT, umbilical cord blood transplantation; TNC, total nucleated cells; CB, cord blood
complications were methicillin-resistant Staphylococcus capitis (MRS) bacteremia, HHV-6 DNAemia, CMV antigenemia, BK virus-associated cystitis, and aGVHD (skin, stage 3, grade 2). MRS was detected on day 3, and vancomycin was administered to control the bacteremia. Prophylactic treatment with foscarnet sodium (PFA) (180 mg/kg/day, weekly) was administered under the monitoring of HHV-6 DNA in peripheral blood on a weekly basis due to the high risk of HHV-6 infection during the 2nd CBT. However, HHV-6 DNAemia and CMV antigenemia were detected on day 14 and day 23, respectively. Thus, pre-emptive treatment with PFA (180 mg/kg/day, daily) was started and controlled. aGVHD of the skin (stage 3, grade 2) was observed on day 40, and was treated through the external administration of prednisolone. BK virus-associated cystitis developed on day 60, and hydration and ciprofloxacin (600 mg/day) were administered. These treatments led to resolution of HHV-6 DNA in peripheral blood on a weekly basis due to the high risk of HHV-6 infection during the 2nd CBT. However, HHV-6 DNAemia and CMV antigenemia were detected on day 14 and day 23, respectively. Thus, pre-emptive treatment with PFA (180 mg/kg/day, daily) was started and controlled. aGVHD of the skin (stage 3, grade 2) was observed on day 40, and was treated through the external administration of prednisolone. BK virus-associated cystitis developed on day 60, and hydration and ciprofloxacin (600 mg/day) were administered. These treatments led to resolution of the MRS bacteremia, HHV-6 DNAemia, CMV antigenemia, BK virus-associated cystitis, and aGVHD. We retrospectively compared the lymphocyte transition between 1st CBT and 2nd CBT. Consistent with a previous report of a transient lymphocyte increase before GF (5) and in hematopoietic stem cell transplantation (HSCT) patients, in our case of 1st CBT, a transient lymphocyte increase occurred before GF (Fig. 2). However, during the clinical course of 2nd CBT, a transient lymphocyte increase did not occur before successful engraftment (Fig. 2). Finally, the patient was discharged on day 120. For 39 months after the treatment, the patient remained disease-free, and did not require further treatment for AML (Fig. 3). Our findings in this case suggest that these treatments may be feasible, safe, and effective for the treatment of patients with GF in CBT.

DISCUSSION

The results of a second transplantation for GF are still poor at approximately 1 year, with an 11% survival rate among 122 patients having been reported. In particular, half of patients who underwent a second transplantation died within 100 days following second transplantation. The major causes of death in these patients were infection, multi-organ failure, and GF. Therefore, elucidation of the pathogenesis of GF and the establishment of an appropriate HSCT source, conditioning regimen, and GVHD prophylaxis are essential for overcoming the poor outcome of second transplantsations.

In our case, the dysfunction of host cells by PIR and HLH may have been associated with the pathogenesis of primary-type GF in the 1st CBT. Furthermore, the patient successfully underwent secondary CBT with a modified one-day

Secondary CBT for graft failure

Fig. 3. Clinical course of the present case. We presented a 28-year-old man, diagnosed with acute myelogenous leukemia with myelodysplasia-related changes. On the basis of poor prognosis factors, the patient underwent a myeloablative conditioning regimen, followed by cord blood transplantation (CBT) in the first complete remission. After primary graft failure was diagnosed on day 27, the patient underwent secondary CBT with a short-term reduced-intensity conditioning regimen, consisting of fludarabine, cyclophosphamide, and total body irradiation, and graft-versus-host disease prophylaxis consisting of mycophenolate and tacrolimus. Consequently, engraftment was achieved on day 17, and the patient remained disease-free for 39 months.

IDA, idarubicin; Ara C, cytosine arabinosine; HDAC, high-dose cytosine arabinosine; CBT, umbilical cord blood transplantation; TBI, total body irradiation; GVHD, graft-versus-host disease; CY, cyclophosphamide; sMTX, short-term methotrexate; CSP, cyclosporine; Flu, fludarabine; MMF, mycophenolate; FK, tacrolimus; HLA, human leukocyte antigen; CR, complete remission.
conditioning regimen consisting of fludarabine, cyclophosphamide, and total body irradiation, and GVHD prophylaxis consisting of MMF and FK. Our case suggests that these treatments may be feasible, safe, and effective for the treatment of patients with GF in CBT. We speculate that a modified one-day conditioning regimen and GVHD prophylaxis contribute to suppression of the activation of donor cells that play a major role in the pathogenesis of GF, and may be reasonable therapeutic modalities. GF is classified into primary GF by an initial lack of donor cells or secondary GF by a loss of donor cells after initial engraftment.13-15 Moreover, primary GF can be subdivided into a rejection or a dysfunction of donor cells.4-15 However, the pathogenesis in the disease progression of GF in CBT is not fully understood. One of the pathogeneses of GF in CBT was reported to be associated with PIR or HLH.16-18 Recently, Koyama et al. reported that a transient increase of lymphocytes before GF may play an important role in the pathogenesis of GF in a mouse model and clinical HSCT patients.19 Moreover, Kuriyama et al. reported that the CD47-signal regulatory protein a antiphagocytic system plays a key role in the maintenance of hematopoietic stem cells, and that its disruption by hematopoietic stem cell-specific CD47 down-regulation may be critical for HLH development.19 Consistent with previous reports,16-19 the findings in our case suggested that PIR and HLH may be associated with the pathogenesis of GF in the 1st CBT.

To achieve a successful 2nd HSCT, it should be essential to consider the source of HSCT, the conditioning regimen, and GVHD prophylaxis based on the pathogenesis of GF. As for the source of HSCT, urgent and appropriate preparation of this should be essential. Thus, we selected the 2nd CB containing total nucleated cells at over \(2 \times 10^7\) cells/kg and CD34+ cells at over \(1 \times 10^5\) cells/kg because of the absence of an appropriate HLA-identical sibling donor or non-sibling donor.

As for the conditioning regimen, to overcome the poor survival of GF, Goggie et al. and Sumi et al. reported some success by an innovative conditioning regimen in the treatment of 2nd CBT.9,10 In particular, Sumi et al. reported a modified one-day regimen consisting of fludarabine (30 mg/m2, days 1-3), cyclophosphamide (2 g/m2), and total body irradiation (2 Gy).18 In our case, we administered 3 consecutive days of fludarabine to control the host immune system due to the presence of persistent HLH before a second HSCT. Furthermore, additional low-dose total body irradiation may assist in successful engraftment, consistent with a previous report regarding the eradication of residual host immune cells in GF by low-dose total body irradiation.20 Among previously reported HSCT patients undergoing a second HSCT with a modified one-day conditioning regimen, the result of the second HSCT for GF was excellent at approximately 1 year, with an 80% survival rate (Table 3). Consequently, we performed the modified one-day conditioning regimen as the conditioning regimen of 2nd HSCT.

As for the GVHD prophylaxis, Uchida et al. reported that a combination of MMF and FK was well tolerated and decreased early non-relapse mortality, possibly through improved control of PIR.21 In our case, we selected the GVHD prophylaxis as a combination of MMF and FK because of the presence of PIR by a transient lymphocyte increase during the 1st CBT. The modified one-day conditioning regimen and GVHD prophylaxis of MMF and FK led to successful second CBT.

Finally, the control of infectious complications was a critical factor in patient outcome. Indeed, during the second

### Table 3. Previously published reports regarding the one day conditioning regimen in the second transplantation for graft failure

| Reference (year) | Age/Disease | Status at retransplantation | Source of HSCT | Engraftment | Treatment outcome |
|------------------|-------------|----------------------------|----------------|-------------|------------------|
| Yamashita et al. (2009) | 56/ML | Rejection/fibrinoid necrotis | CB→CB | 19 days | Alive, > 60 mon |
| Yamashita et al. (2009) | 66/AML | Relapse/pulmonary aspergillosis | CB→CB | 17 days | Alive, > 53 mon |
| Sumi et al. (2010) | 42/AML | Rejection/P. aeruginosa sepsis | CB→CB | 25 days | Alive, > 53 mon |
| Sumi et al. (2010) | 20/ALL | Rejection/MRSE sepsis | BM→CB | 26 days | Dead (relapse), 13 mon |
| Sumi et al. (2010) | 34/CML | Rejection | CB→CB | 18 days | Alive, > 28 mon |
| Sumi et al. (2010) | 37/AML | Rejection/streptococceus sepsis | CB→PB | 10 days | Alive, > 27 mon |
| Sumi et al. (2010) | 53/AML | MRSE sepsis | CB→CB | 20 days | Dead (HLH), 2 mon |
| Sumi et al. (2010) | 68/AA | MRSE sepsis | CB→CB | 24 days | Alive, > 14 mon |
| Present case | 26/AML | Rejection | CB→CB | 17 days | Alive, > 59 mon |

ML, malignant lymphoma; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; AA, aplastic anemia; MRSE, methicillin-resistant Staphylococcus epidermidis; HSCT, hematopoietic stem cell transplantation; BM, bone marrow; PB, peripheral blood; CB, cord blood; HLH, hemophagocytic lymphohistiocytosis
CBT, there was a high risk of the development of HHV-6 encephalitis. Therefore, we monitored HHV-6 DNA in peripheral blood on a weekly basis. Moreover, PFA (180 mg/kg) was administered on a weekly basis, in a prophylactic therapeutic manner. Moreover, when CMV antigenemia occurred, we administered PFA (180 mg/kg) on a daily basis, in a pre-emptive therapeutic manner. Consistent with previous reports, PFA, with less toxicity than myelosuppression, may be an effective and reasonable therapeutic strategy for the control of CMV and HHV-6 infections in the second setting of CBŚCT.

In conclusion, our findings in this case suggest that these treatments may be a feasible, safe, and effective strategy for patients with GF in CBT. A randomized study and longer follow-up period will be necessary for the assessment of this therapeutic modality. This case study may be helpful to physicians who directly care for GF patients, and may provide a future direction for a more efficient treatment modality.

ACKNOWLEDGMENTS

We thank Ms. Kugimiya, Ms. Sakurai, and Ms. Kiyoyama for carefully examining the bone marrow specimens.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

REFERENCES

1. Arber A: Acute myeloid leukemia with myelodysplasia-related changes. In: Serdow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (eds): World Health Organization Classification of Tumours, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, International Agency for Research on Cancer (IARC), pp.124-126, 2008
2. Roboz GJ: Current treatment of acute myeloid leukemia. Curr Opin Oncol 24:711-719, 2012
3. Estey EH: Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88:318-327, 2013
4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, et al.: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
5. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
6. Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, et al.: Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematologic diseases. Clin Cancer Res 10:3586-3592, 2004
7. Yuji K, Miyakoshi S, Kato D, Miura Y, Myojo T, et al.: Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 11:314-318, 2005
8. Goggin TF, Rizzieri DA, Prosnitz R, Gasparetto C, Long G, et al.: One day preparative regimen for allogeneic non-myeloablative stem cell transplantation (NMSCT) using 3-5/6 HLA matched related donors. Blood 102:476b-477b, 2003 (abstract)
9. Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, et al.: Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol 92:744-750, 2010
10. Shimizu I, Kobayashi H, Nasu K, Otsuki F, Ueki T, et al.: Successful engraftment of cord blood following a one-day reduced-intensity conditioning regimen in two patients suffering primary graft failure and sepsis. Bone Marrow Transplant 44:617-618, 2009
11. Yamashita T, Sugimori C, Ishiyama K, Yamazaki H, Okumura H, et al.: Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. Int J Hematol 89:238-242, 2009
12. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
13. Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, et al.: Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant 49:110-115, 2015
14. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, et al.: Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 16:1099-1106, 2010
15. Offner F, Schoch G, Fisher LD, Torok-Storb B, Martin P: Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood 88:4058-4062, 1996
16. Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, et al.: Rapid T-cell chimerism switch and memory T-cell expansion are associated with pre-engraftment immune reaction early after cord blood transplantation. Br J Haematol 160:255-258, 2013
17. Yamashita T, Sugimori C, Ishiyama K, Yamazaki H, Okumura H, et al.: Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. Int J Hematol 89:238-242, 2009
18. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, et al.: Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 16:1099-1106, 2010
19. Offner F, Schoch G, Fisher LD, Torok-Storb B, Martin P: Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood 88:4058-4062, 1996
20. Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, et al.: Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 80:34-40, 2005
21. Matsuno N, Yamamoto H, Watanabe N, Uchida N, Ota H, et al.: Rapid T-cell chimerism switch and memory T-cell expansion are associated with pre-engraftment immune reaction early after cord blood transplantation. Br J Haematol 160:255-258, 2013
22. Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, et al.: Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation 92:366-371, 2011
23. Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, et al.: Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation 92:366-371, 2011
Kawano N, et al.

cytic lymphohistiocytosis. Blood 120:4058-4067, 2012

20 Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, et al.: Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transplant 15:1314-1322, 2009

21 Ogata M, Satou T, Kawano R, Goto K, Ikewaki J, et al.: Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 41:279-285, 2008

22 Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, et al.: Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 193:68-79, 2006

23 Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, et al.: High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant 16:1596-1602, 2010

24 Reusser P, Einsele H, Lee J, Velin L, Rovira M, et al.: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159-1164, 2002

25 Ishiyama K, Katagiri T, Ohata K, Hosokawa K, Kondo Y, et al.: Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis 14:33-39, 2012